These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20153921)

  • 1. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
    Zhu H; Cao X; Ali-Osman F; Keir S; Lo HW
    Cancer Lett; 2010 Aug; 294(1):101-10. PubMed ID: 20153921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
    Sun Q; Ming L; Thomas SM; Wang Y; Chen ZG; Ferris RL; Grandis JR; Zhang L; Yu J
    Oncogene; 2009 Jun; 28(24):2348-57. PubMed ID: 19421143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis.
    Cao X; Zhu H; Ali-Osman F; Lo HW
    Mol Cancer; 2011 Mar; 10():26. PubMed ID: 21388543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
    Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
    Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
    Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
    Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
    Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
    Cemeus C; Zhao TT; Barrett GM; Lorimer IA; Dimitroulakos J
    J Neurooncol; 2008 Oct; 90(1):9-17. PubMed ID: 18566746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
    Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
    Hegi ME; Diserens AC; Bady P; Kamoshima Y; Kouwenhoven MC; Delorenzi M; Lambiv WL; Hamou MF; Matter MS; Koch A; Heppner FL; Yonekawa Y; Merlo A; Frei K; Mariani L; Hofer S
    Mol Cancer Ther; 2011 Jun; 10(6):1102-12. PubMed ID: 21471286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
    Wykosky J; Hu J; Gomez GG; Taylor T; Villa GR; Pizzo D; VandenBerg SR; Thorne AH; Chen CC; Mischel PS; Gonias SL; Cavenee WK; Furnari FB
    Cancer Res; 2015 Jan; 75(2):394-404. PubMed ID: 25432173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
    Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
    Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.
    Liu XJ; Wu WT; Wu WH; Yin F; Ma SH; Qin JZ; Liu XX; Liu YN; Zhang XY; Li P; Han S; Liu KY; Zhang JM; He QH; Shen L
    CNS Neurosci Ther; 2013 Jul; 19(7):494-502. PubMed ID: 23575351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
    Guo D; Prins RM; Dang J; Kuga D; Iwanami A; Soto H; Lin KY; Huang TT; Akhavan D; Hock MB; Zhu S; Kofman AA; Bensinger SJ; Yong WH; Vinters HV; Horvath S; Watson AD; Kuhn JG; Robins HI; Mehta MP; Wen PY; DeAngelis LM; Prados MD; Mellinghoff IK; Cloughesy TF; Mischel PS
    Sci Signal; 2009 Dec; 2(101):ra82. PubMed ID: 20009104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
    Li L; Puliyappadamba VT; Chakraborty S; Rehman A; Vemireddy V; Saha D; Souza RF; Hatanpaa KJ; Koduru P; Burma S; Boothman DA; Habib AA
    Oncogene; 2015 Jan; 34(1):129-134. PubMed ID: 24362532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.